ADVERTISEMENT
News » Money
Oct 28, 8:19 AM EDT

Pfizer beats Wall Street estimates with 3Q growth of drugs and vaccines in emerging markets


AP Photo
AP Photo/Mark Lennihan
Business Video

Multimedia
When Drugs Stop Working
Lone Protestor Rallies Ohio City Against Drugs
From Drug Addict to Counselor
Documents
CDC Report on Sexual Behavior and Drug Use
Latest News
State Medicaid chiefs ask Congress to consider price controls for costly new drugs

Dietary supplements may contain risky prescription drugs even after safety recalls, study says

Leading gay-rights group endorses use of HIV-prevention pill, urges broader insurance coverage

North Carolina drugmaker to test drug for Ebola after getting FDA permission

Buy AP Photo Reprints

WASHINGTON (AP) -- Pfizer reported better-than-expected third quarter earnings Tuesday as higher sales in emerging markets like China helped offset missing revenue from former blockbuster drugs that have lost patent protection.

The New York drugmaker reported third-quarter profit of $2.67 billion, or 42 cents per share, up from $2.59 billion, or 39 cents a share, in the prior-year period. Excluding one-time costs and discontinued operations the company would have earned 57 cents per share.

That was better than the average Wall Street estimate of analysts surveyed by Zacks Investment Research, who called for 56 cents per share.

Revenue slipped 2 percent to $12.36 billion but the company did see growth from drugs and vaccines in emerging markets, particularly its Prevnar vaccine against pneumonia. Analysts expected $12.16 billion in revenue for the period, according to Zacks.

Like many other drugmakers, Pfizer has lost patent exclusivity on several of its biggest blockbuster drugs that had raked in billions annually. Those are led by cholesterol fighter Lipitor, which lost patent protection in November 2011 after nearly a decade as the world's top-selling drug.

Pfizer executives highlighted the company's growth in emerging markets, which grew 9 percent in the quarter, helped by sales of Prevnar and Lipitor in China.

"Overall, I am pleased with our third-quarter 2014 financial results despite the continued negative impact from product losses of exclusivity and the termination of certain co-promotion collaborations," CFO Frank D'Amelio said in a prepared statement.

Last spring, Pfizer made an unsuccessful bid to buy British drugmaker AstraZeneca for $119 billion, which would have been the largest deal in pharmaceutical history. Besides gaining AstraZeneca's drugs and pipeline, Pfizer wanted to move its legal headquarters to England to get a lower tax rate than it faces in the U.S., a strategy called "inversion" that is suddenly hot in corporate America.

CEO Ian Read did not offer any hints of potential future acquisition targets for the company, stating only that Pfizer executives "remain opportunistic regarding business development that can enhance or accelerate our strategy."

Pfizer expects full-year earnings in the range of $2.23 to $2.27 per share, from a prior estimate of $2.20 to $2.30. The company predicts full-year revenue in the range of $48.7 billion to $49.7 billion.

Pfizer shares have dropped 5 percent since the beginning of the year, while the Standard & Poor's 500 index has risen 6 percent. The stock has declined 5 percent in the last 12 months.

-----

This story includes elements generated by Automated Insights using data from Zacks Investment Research. PFE stock research report from Zacks.

-----

Keywords:Pfizer,Earnings Report,Priority Earnings

© 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy and Terms of Use.

 
ADVERTISEMENT